Cancer
Scientists at The Wistar Institute have discovered that FDA-approved PARP1 inhibitors can effectively combat Epstein-Barr virus (EBV)-driven lymphomas by disrupting a key cancer pathway. The study found that PARP1 inhibitors, which block the activity of the PARP1 enzyme, can halt tumor growth by interfering with the EBV's
Cancer
Scientists at The Wistar Institute have made a significant discovery about the mechanisms by which the Epstein-Barr virus (EBV) reprograms B cells to facilitate cancer development. EBV, which infects over 90% of the world's population, typically causes mild or no symptoms but can lead to serious diseases, including
Cancer research
Researchers from Xidian University have made significant progress in developing a new treatment for cancer using gene therapy combined with epigenetic regulation. The study, published in Trends in Biotechnology, describes a technology that uses alphavirus-based gene therapy to deliver a cancer-fighting gene, p53, into tumor cells. This approach has shown
Cancer research
Recent research by Binzhou Medical University has highlighted the significance of the p53 gene in cancer treatment, despite challenges in developing effective therapies. The p53 gene, a nuclear transcription factor, has been labeled "undruggable" due to its characteristics, but promising strategies have emerged to target proteins considered previously
Cancer research
Researchers in Nanjing, People's Republic of China, have been exploring the potential of nanomedicine in treating gastritis and gastric cancer. According to a recent study, nanomedicine has emerged as a promising therapeutic approach, particularly through targeted drug delivery systems and combination therapies. This research aims to improve the
Cancer research
Cancer remains a complex global health challenge due to its resistant nature to conventional treatments. A recent study by Texas A&M University-Corpus Christi researchers sheds light on innovative solutions in cancer gene therapy, exploring how nanoparticle-based strategies can enhance the efficacy of chemotherapy, radiotherapy, phototherapy, immunotherapy, and gene
Cancer
A new study published in the journal Nucleosides, Nucleotides & Nucleic Acids has made a significant discovery in the field of biotechnology-bioinformatics. Researchers from the School of Pharmacy, Yancheng Teachers' University, have identified a potential cancer risk marker in the Chinese population, which could lead to improved diagnosis and
Cancer research
Researchers at China Pharmaceutical University have made a significant breakthrough in cancer gene therapy, developing a targeted delivery system that uses nanocrystals to deliver anti-inflammatory baicalein and miR138 gene therapy against pulmonary arterial hypertension (PAH). This innovative approach has shown promising results in improving pulmonary hemodynamics and reducing PA thickness
Cancer
A recent study has revealed novel gene signatures associated with developing resistance to PARP-1 inhibitors, specifically Olaparib, which are used as the first line of treatment for various cancer types, including breast, ovarian, pancreatic, and prostate cancers. Researchers from the National Institute of Pharmaceutical Education and Research identified 139 common
Cancer
Researchers from the KTH Royal Institute of Technology in Solna, Sweden have made a significant advancement in the field of cancer gene therapy, discovering that nanoscale biological particles play crucial roles in health and disease. The study, supported by Vetenskapsradet, Karolinska Institutet, and the Human Frontier Science Program, among others,
Cancer research
Researchers at Cairo University have made significant strides in the development of alternative therapeutic strategies for tongue cancer, one of the most aggressive and deadly forms of the disease. According to a recent study, calcium titanate nanoparticles (CaTiO3NPs) demonstrated strong and selective multi-modal cytotoxic effects against HNO-97 tongue cancer cells
Cancer research
Researchers from the Medical School of Nanchang University have made a significant discovery in understanding the role of circulating tumor DNA (ctDNA) in predicting long-term outcomes in non-small cell lung cancer (NSCLC) patients. By analyzing ten studies involving 1859 cases, the team found that positive ctDNA-based molecular residual disease (MRD)
